# Fifth Circuit Upholds DOJ Suit Dismissal

The U.S. Court of Appeals for the Fifth Circuit affirmed dismissal of Brook Jackson’s False Claims Act suit alleging that Pfizer contractor Ventavia Research Group engaged in fraud during a COVID-19 vaccine trial. The court upheld the Department of Justice’s intervention and request to dismiss the whistleblower case, applying the framework discussed in the Supreme Court’s 2023 Polansky decision. This is a litigation and contractor-risk signal, not a new procurement opportunity or a new compliance mandate.

- For contractors supporting clinical research, the case illustrates how DOJ’s decision to intervene and seek dismissal can affect False Claims Act litigation.
- Organizations may find it useful to review their trial documentation and internal controls in light of the fraud allegations, while recognizing that the court’s decision does not establish new procurement requirements.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** November 13, 2026

### Government Entities
- U.S. Department of Justice (DOJ)
- U.S. Court of Appeals for the Fifth Circuit (Fifth Circuit)
- Supreme Court of the United States (U.S. Supreme Court)

### Vendors
- Ventavia Research Group LLC (Clinical-trial contractor to Pfizer)